<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30806" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Uremia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zemaitis</surname>
            <given-names>Michael R.</given-names>
          </name>
          <aff>Carepoint Health Bayonne Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Foris</surname>
            <given-names>Lisa A.</given-names>
          </name>
          <aff>St. George's University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Katta</surname>
            <given-names>Shravan</given-names>
          </name>
          <aff>Texas Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bashir</surname>
            <given-names>Khalid</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Zemaitis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lisa Foris declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shravan Katta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khalid Bashir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30806.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Uremia is a clinical condition associated with declining renal function and is characterized by fluid overload, electrolyte imbalances, metabolic abnormalities, and physiological changes. The term "uremia" literally means "urine in the blood,"&#x000a0;which develops most commonly&#x000a0;in chronic and end-stage renal disease. However, less commonly, this condition can also manifest in acute kidney injury if kidney function deteriorates rapidly. Urea exhibits direct and indirect toxicity to various tissues, notably affecting the neurological system. Urea acts as a marker&#x000a0;for uremic toxins in general, with over 100 substances identified as potential uremic toxins, which are present in varying concentrations in the blood.&#x000a0;Urea and other uremic toxins, accumulated due to impaired renal clearance, are toxic to various tissues, especially the nervous system, leading to symptoms such as nausea, vomiting, fatigue, anorexia, muscle cramps, pruritus, and altered mentation. These manifestations significantly diminish a patient's quality of life and, if left untreated, can result in morbidity and mortality.</p>
        <p>Due to the frequent occurrence of altered mental status in patients, early recognition by healthcare professionals is crucial for promptly initiating renal replacement therapy and potential renal transplant referral, leading to improved patient outcomes. Healthcare professionals must also vigilantly monitor for any signs of uremia to prevent associated complications. Timely referral to transplantation centers is associated with improved survival rates and reduced morbidity among uremia patients.&#x000a0;This activity reviews the evaluation and management of uremia, emphasizing the collaborative role of interprofessional team members in delivering well-coordinated care to improve outcomes for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify early signs and symptoms of uremia, including nausea, vomiting, fatigue, altered mentation, and electrolyte imbalances,&#x000a0;to facilitate prompt diagnosis and treatment initiation.</p></list-item><list-item><p>Implement evidence-based interventions for managing uremia-related complications such as fluid overload, electrolyte imbalances, and metabolic abnormalities.</p></list-item><list-item><p>Assess renal function using appropriate laboratory tests and imaging modalities to monitor disease progression and treatment effectiveness.</p></list-item><list-item><p>Coordinate care across healthcare settings to ensure seamless transitions and continuity of care for patients undergoing renal replacement therapy and transplantation.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30806&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30806">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30806.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Uremia is a clinical condition associated with declining renal function and is characterized by fluid overload, electrolyte imbalances, metabolic abnormalities, and physiological changes. The term "uremia" literally means "urine in the blood,"&#x000a0;which develops most commonly&#x000a0;in chronic and end-stage renal disease. However, less commonly, this condition can also manifest in acute kidney injury if kidney function deteriorates rapidly.&#x000a0;Urea exhibits direct and indirect toxicity to various tissues, notably affecting the neurological system.<xref ref-type="bibr" rid="article-30806.r1">[1]</xref><xref ref-type="bibr" rid="article-30806.r2">[2]</xref>&#x000a0;</p>
        <p>Urea acts as a marker&#x000a0;for uremic toxins&#x000a0;in general, with over 100 substances identified as potential uremic toxins, which are present in varying concentrations in the blood. These substances are often metabolites that cannot be cleared due to impaired renal function. In addition to urea, other putative uremic toxins comprise parathyroid hormone, &#x003b1;-macroglobulin, advanced glycosylation end products, indoxyl sulfate, homocysteine, uric acid, and &#x003b2;-2 microglobulin. The clinical manifestations of uremia are not attributed to a single uremic toxin; instead, a combination of multiple toxins likely contributes to the physiological and clinical features of uremia.<xref ref-type="bibr" rid="article-30806.r3">[3]</xref><xref ref-type="bibr" rid="article-30806.r4">[4]</xref><xref ref-type="bibr" rid="article-30806.r5">[5]</xref><xref ref-type="bibr" rid="article-30806.r6">[6]</xref></p>
        <p>Urea and other uremic toxins, accumulated due to impaired renal clearance, are toxic to various tissues, especially the nervous system, leading to symptoms such as nausea, vomiting, fatigue, anorexia, muscle cramps, pruritus, and altered mentation.<xref ref-type="bibr" rid="article-30806.r7">[7]</xref><xref ref-type="bibr" rid="article-30806.r8">[8]</xref>&#x000a0;These&#x000a0;manifestations significantly diminish a patient's quality of life and, if left untreated, can result in morbidity and mortality.<xref ref-type="bibr" rid="article-30806.r9">[9]</xref> Uremic signs and symptoms typically develop gradually over time. Due to the frequent occurrence of altered mental status in patients, early recognition by healthcare professionals is crucial for promptly initiating renal replacement therapy and potential renal transplant referral. Furthermore, healthcare providers should&#x000a0;provide guidance and make necessary arrangements for patients requiring renal replacement therapy to improve their health outcomes.&#x000a0;They must also vigilantly monitor for any signs of uremia to prevent associated complications. Timely referral to transplantation centers is associated with improved survival rates and reduced morbidity among uremia patients.&#x000a0;</p>
      </sec>
      <sec id="article-30806.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Uremia can arise from various conditions, ranging from primary renal disorders such as immunoglobulin A (IgA) nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, and polycystic kidney disease to systemic disorders that cause renal damage. Systemic disorders include conditions such as diabetes mellitus, systemic lupus erythematosus, multiple myeloma, amyloidosis, antiglomerular basement membrane disease, thrombotic thrombocytopenic purpura, or hemolytic uremic syndrome.</p>
        <p>Diabetes is the leading cause of ESRD in the United States, accounting for 40% of new dialysis patients. Additional causes, listed in order of decreasing incidence, include hypertension, glomerulonephritis, interstitial disease, cystitis, and neoplasms. Globally, diabetes remains the primary cause of kidney failure; nonetheless, glomerulonephritis emerges as the predominant underlying cause in developing nations.</p>
        <p>Uremia may also result from&#x000a0;acute kidney injury if the injury involves a sudden increase in urea or creatinine levels.<xref ref-type="bibr" rid="article-30806.r10">[10]</xref><xref ref-type="bibr" rid="article-30806.r11">[11]</xref><xref ref-type="bibr" rid="article-30806.r12">[12]</xref>&#x000a0;Notably, uremia likely stems from the retention of various toxic biochemicals that may act synergistically. Numerous studies have associated different toxins with uremic symptoms, and <italic toggle="yes">i</italic><italic toggle="yes">n vitro</italic> experimental models have shown associated adverse effects.<xref ref-type="bibr" rid="article-30806.r6">[6]</xref><xref ref-type="bibr" rid="article-30806.r13">[13]</xref><xref ref-type="bibr" rid="article-30806.r14">[14]</xref>&#x000a0;These toxins may vary in their solubility in water or binding to proteins, and they may have different molecular weights.<xref ref-type="bibr" rid="article-30806.r15">[15]</xref>&#x000a0;In addition, evidence indicates that certain anti-inflammatory and vasodilator compounds, such as glutathione and arginine, are reduced in renal failure, which could also contribute to some aspects of uremic pathology.<xref ref-type="bibr" rid="article-30806.r6">[6]</xref><xref ref-type="bibr" rid="article-30806.r13">[13]</xref></p>
      </sec>
      <sec id="article-30806.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Determining the exact prevalence of uremia in the United States poses challenges because patients with ESRD often start dialysis before exhibiting uremic symptoms. Uremic symptoms typically manifest when creatinine clearance drops below 10 or 15 mL/min in diabetic patients. According to the United States Renal Data System (USRDS) 2009 data, the reported incidence and prevalence of advanced chronic kidney disease (CKD) in the United States were 354 and 1665 per million people per year, respectively. In 2009, 116,395 patients initiated renal replacement therapy, yielding an unadjusted incidence rate of 371 per million.<xref ref-type="bibr" rid="article-30806.r16">[16]</xref>&#x000a0;This number continues to rise as the life expectancy of those with ESRD is increasing.</p>
        <p>Improved survival rates among patients with diabetes or cardiovascular disease, coupled with improved access to renal therapy, have led to a notable increase in the incidence of ESRD among individuals aged 75 or older. Conversely, there is a declining trend in the number of individuals aged 60 or younger with ESRD, except for Black or Native American patients with diabetic ESRD.&#x000a0;Japan has the highest prevalence of&#x000a0;ESRD patients in the world, followed by Taiwan.<xref ref-type="bibr" rid="article-30806.r17">[17]</xref>&#x000a0;Remarkably, only 5&#x000a0;countries account for 58% of the world's ESRD patients&#x02014;the United States, Japan, Brazil, Germany, and Italy.<xref ref-type="bibr" rid="article-30806.r18">[18]</xref></p>
        <p>The majority of patients with ESRD&#x000a0; are White (59.8%), with the remaining patients being Black (33.2%), Asian (3.6%), or Native American (1.6%). However, the incidence of ESRD among Black individuals is 3.7 times higher than among the White population. Similarly, the incidence among Native Americans is 1.8 times greater than among the White population.&#x000a0;Additionally, minority populations tend to&#x000a0;initiate dialysis care later in the course of&#x000a0;renal disease, usually&#x000a0;after a significant decline in the glomerular filtration rate (GFR). However, it remains uncertain whether racial or ethnic backgrounds influence the predisposition to developing uremic symptoms.</p>
        <p>Men are 1.2 times more likely to develop ESRD than women, although women are 1.7 times more likely to delay the initiation of dialysis than men. Furthermore, women are more susceptible to developing uremic symptoms at lower creatinine levels, attributed to their reduced muscle mass and lower baseline serum creatinine levels.<xref ref-type="bibr" rid="article-30806.r19">[19]</xref><xref ref-type="bibr" rid="article-30806.r20">[20]</xref><xref ref-type="bibr" rid="article-30806.r21">[21]</xref></p>
      </sec>
      <sec id="article-30806.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Impaired kidney function can lead to dysregulation in several vital processes, including acid-base balance, fluid and electrolyte regulation, hormone production and secretion, and waste elimination. Collectively, these dysfunctions contribute to metabolic disturbances and give rise to conditions such as anemia, coagulopathy, metabolic acidosis, hyperkalemia, hyperparathyroidism, and cardiac dysfunction.</p>
        <p>Anemia associated with kidney disease is typically characterized as normocytic, normochromic, and hypoproliferative. The condition arises due to reduced erythropoietin production by the failing kidneys and is associated with a GFR of less than 50 mL/min (or GFR &#x0003c;60 mL/min with diabetes) or when serum creatinine exceeds 2 mg/dL.<xref ref-type="bibr" rid="article-30806.r22">[22]</xref>&#x000a0;Additional factors associated with CKD alone may further contribute to the development of anemia. These factors include iron or vitamin deficiencies, hyperparathyroidism, hypothyroidism, or a decreased lifespan of red blood cells.&#x000a0;Studies have&#x000a0;revealed that hepcidin, an acute-phase protein, is involved with iron metabolism and plays a crucial role in erythropoiesis. During inflammatory states, hepcidin levels increase, inhibiting iron absorption from the small intestine and iron release from macrophages.<xref ref-type="bibr" rid="article-30806.r23">[23]</xref></p>
        <p>The accumulation of uremic toxins in the blood can also contribute to the development of coagulopathy. This occurs due to reduced platelet adhesion to the vascular endothelial wall, increased platelet turnover, and a slight decrease in the absolute number of platelets.<xref ref-type="bibr" rid="article-30806.r24">[24]</xref>&#x000a0;Bleeding diathesis, which refers to an increased susceptibility to bleeding and hemorrhage, is a common observation in patients with ESRD.</p>
        <p>Another major metabolic complication associated with uremia and ESRD is acidosis, as renal tubular cells are the primary regulators of acid-base balance in the body. With progressive kidney failure, metabolic changes include reduced secretion of hydrogen ions, impaired excretion of ammonium, and eventual accumulation of phosphate and other organic acids such as lactic acid, sulfuric acid, and hippuric acid. Consequently, heightened metabolic acidosis can lead to symptoms such as hyperventilation, lethargy, anorexia, muscle weakness, and congestive heart failure due to decreased cardiac contractility.</p>
        <p>Hyperkalemia can occur in acute and chronic renal failure settings, and it becomes a medical emergency when serum potassium levels exceed 6.5 mEq/L. Excessive potassium intake or the use of certain medications, such as potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, &#x003b2;-blockers, and non-steroidal anti-inflammatory drugs (NSAIDs), can exacerbate this level.<xref ref-type="bibr" rid="article-30806.r25">[25]</xref> Acidosis resulting from renal failure may also contribute to the development of hyperkalemia.</p>
        <p>Renal failure can lead to hypocalcemia, hyperphosphatemia, and elevated parathyroid hormone levels. Hypocalcemia results from decreased production of active vitamin D (1,25 dihydroxyvitamin D), which normally facilitates gastrointestinal absorption of calcium and phosphorus and suppresses parathyroid hormone excretion. Hyperphosphatemia occurs due to impaired phosphate excretion in renal failure. Both hypocalcemia and hyperphosphatemia stimulate parathyroid gland hypertrophy, leading to increased parathyroid hormone production and secretion. These changes in calcium metabolism can contribute to renal osteodystrophy (known as CKD-metabolic bone disease) and may cause calcium deposition throughout the body (metastatic calcification).<xref ref-type="bibr" rid="article-30806.r26">[26]</xref></p>
        <p>Declining renal function can result in decreased insulin clearance, necessitating a decrease in the dosage of antihyperglycemic medications to prevent hypoglycemia. Uremia can also cause impotence in men or infertility in women, manifested as dysfunctional reproductive hormone regulation, such as anovulation or amenorrhea.</p>
        <p>The buildup of uremic toxins may also contribute to uremic pericarditis and pericardial effusions, leading to abnormalities in cardiac function. When coupled with metastatic calcification due to declining renal function, these factors may exacerbate underlying valvular dysfunction or suppression of myocardial contractility.<xref ref-type="bibr" rid="article-30806.r27">[27]</xref><xref ref-type="bibr" rid="article-30806.r28">[28]</xref></p>
      </sec>
      <sec id="article-30806.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Symptomatic uremia typically occurs when creatinine clearance drops below 10 to 20 mL/min unless kidney failure develops acutely. In such cases, some patients may experience symptoms even at higher clearance rates. Patients with uremia may present with various symptoms, including nausea, vomiting, fatigue, anorexia, weight loss, dysgeusia (bad taste in the mouth), chest pain, palpitations, dyspnea, muscle cramps, restless legs, pruritus, easy bleeding, or mental status changes. Neurological symptoms such as confusion, forgetfulness, and memory loss in uremia may have a gradual onset, often unnoticed by patients themselves. Therefore, physicians must maintain a high index of suspicion for uremic symptoms, and obtaining a corroborating history from family members or caregivers becomes crucial. The metabolic disturbances linked to uremia contribute to its clinical presentation, including fatigue due to anemia. Diagnosing uremia in young children can be challenging due to the nonspecific nature of clinical manifestations.</p>
        <p>Hypertension, atherosclerosis, valvular stenosis and insufficiency, chronic heart failure, and angina can all develop due to the accumulation of uremic toxins and metastatic calcification associated with uremia and ESRD. If treatment is not initiated promptly, these abnormalities may contribute to the clinical manifestations of uremia. Occult gastrointestinal bleeding, resulting from platelet abnormalities, may present with nausea or vomiting.<xref ref-type="bibr" rid="article-30806.r29">[29]</xref></p>
        <p>Uremia can have a profound impact on the central nervous system, leading to uremic encephalopathy characterized by symptoms such as fatigue, malaise, somnolence, confusion, memory problems, seizures, stupor, and coma. Additionally, nervous system manifestations may include muscle weakness, restless legs, headache, asterixis, polyneuritis, hyperreflexia, myoclonus, and muscle cramps.<xref ref-type="bibr" rid="article-30806.r30">[30]</xref>&#x000a0;Amyloid deposits could result in medial carpal tunnel syndrome, neuropathy, or other nerve entrapment syndromes. Dermatologic findings, including&#x000a0;skin color changes, xerosis, pruritus, bullous dermatosis, and metastatic calcinosis, as well as hair, nail, and oral mucosa changes, are also prevalent.</p>
        <p>Typical physical examination findings in patients with uremia include signs associated with anemia, fluid retention, and acidemia. In addition, severe malnutrition may result in muscle wasting, while electrolyte abnormalities could lead to muscle cramping, mental status changes, and cardiac arrhythmias. Other commonly observed examination findings in patients with uremia include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Uremic frost (whitish urea crystals deposited on the skin)&#x000a0;<xref ref-type="bibr" rid="article-30806.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Uremic fetor (urine-like odor of the breath)</p>
          </list-item>
          <list-item>
            <p>Gingival hyperplasia, petechiae, enamel hypoplasia, or gingival bleeding&#x000a0;<xref ref-type="bibr" rid="article-30806.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Pericardial rub</p>
          </list-item>
          <list-item>
            <p>Pulmonary edema (rales, decreased breath sounds at lung bases)</p>
          </list-item>
          <list-item>
            <p>Peripheral edema</p>
          </list-item>
          <list-item>
            <p>Severe hypertension</p>
          </list-item>
          <list-item>
            <p>Facial swelling</p>
          </list-item>
          <list-item>
            <p>Asterixis</p>
          </list-item>
          <list-item>
            <p>Papilledema</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30806.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosing renal failure relies on abnormalities in GFR or creatinine clearance.<xref ref-type="bibr" rid="article-30806.r33">[33]</xref>&#x000a0;Differentiating between acute and chronic renal failure is crucial due to the potential reversibility of acute kidney injury. Laboratory studies evaluating hemoglobin, calcium, phosphate, parathyroid hormone, albumin, potassium, and bicarbonate levels, along with urinalysis (including microscopic examination), aid in identifying potential etiologies underlying uremic symptoms.</p>
        <p>A 24-hour urine collection can offer insights into GFR and creatinine clearance, although this method can be burdensome and may yield inaccuracies if not collected precisely. Another option is a nuclear medicine radioisotope (iothalamate) clearance assay that directly measures GFR. However, this test is time-consuming and expensive compared to the Cockcroft-Gault or Modification of Diet in Renal Disease formulas, which are commonly used alternatives.</p>
        <p>According to the National Kidney Foundation, patients with CKD are staged based on their estimated GFR, which is calculated using the&#x000a0;Modification of Diet in Renal Disease&#x000a0;formula.</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1: Normal GFR (90 mL/min or greater)</p>
          </list-item>
          <list-item>
            <p>Stage 2: Mildly reduced GFR (60-90 mL/min)</p>
          </list-item>
          <list-item>
            <p>Stage 3a: Moderately reduced GFR (45-59 mL/min)</p>
          </list-item>
          <list-item>
            <p>Stage 3b: Moderate-to-severely reduced GFR (30-44 mL/min)</p>
          </list-item>
          <list-item>
            <p>Stage 4: Severely reduced GFR (15-29 mL/min)</p>
          </list-item>
          <list-item>
            <p>Stage 5: ESRD (GFR &#x0003c;15 mL/min or patient is on dialysis)</p>
          </list-item>
        </list>
        <p>A renal ultrasound helps determine the size and shape of the kidneys and evaluates hydronephrosis and ureteral/bladder obstruction. These issues may stem from various causes such as kidney stones, neurologic abnormalities, trauma, pregnancy, prostate enlargement, retroperitoneal fibrosis, or abdominal tumors (linked to cervical or prostate cancers), among other structural abnormalities. Conditions such as early diabetic nephropathy, multiple myeloma, polycystic kidney disease, and HIV-associated glomerulonephritis may present with enlarged kidneys on ultrasound.<xref ref-type="bibr" rid="article-30806.r34">[34]</xref></p>
        <p>Smaller, echogenic kidneys indicate more chronic, irreversible changes resulting from long-standing kidney disease, ischemic nephropathy, or hypertensive nephrosclerosis.&#x000a0;Patients with uremia secondary to urinary obstruction should undergo Foley catheterization to relieve the obstruction. Afterward, the cause of obstruction should be evaluated, and a permanent management plan should be implemented.</p>
        <p>Measuring urine protein excretion is valuable in diagnosing glomerulopathies, which can lead to ESRD. Recent evidence suggests that alterations in dipstick proteinuria levels independently predict the risk of ESRD. Monitoring changes in proteinuria over 2 years can provide insights for predicting the risk of ESRD.<xref ref-type="bibr" rid="article-30806.r35">[35]</xref></p>
        <p>A brain computed tomography (CT) scan may be warranted for patients showing significant changes in mental status. Uremic patients with elevated blood urea nitrogen levels (greater than 150-200 mg/dL) are at an increased risk of developing spontaneous subdural hematomas. Due to the heightened risk of bleeding and hemorrhage in uremia, especially following falls or trauma, a CT scan of the brain and abdomen may also be warranted. Furthermore, an abdominal CT scan can help better understand the underlying cause of hydronephrosis if observed on ultrasound.</p>
        <p>Magnetic resonance imaging (MRI) can be useful in evaluating renal artery stenosis, thrombosis, or aortic and renal artery dissection, which are potentially reversible causes of renal failure. Additionally, a renal biopsy can aid in determining the reversibility or treatability of renal injury and may be necessary for accurately diagnosing acute kidney injury or CKD. However, in cases of small kidneys, a biopsy should be avoided due to associated comorbidities, increased risk of bleeding, and a lower likelihood of identifying a reversible process.<xref ref-type="bibr" rid="article-30806.r36">[36]</xref></p>
      </sec>
      <sec id="article-30806.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Dialysis is recommended for any patient experiencing symptomatic uremia, such as nausea, vomiting, refractory hyperkalemia, or metabolic acidosis, that cannot be managed through medical interventions. The presence of uremic symptoms warrants the initiation of dialysis irrespective of the patient's GFR.<xref ref-type="bibr" rid="article-30806.r37">[37]</xref><xref ref-type="bibr" rid="article-30806.r38">[38]</xref><xref ref-type="bibr" rid="article-30806.r39">[39]</xref>&#x000a0;In cases of uremic emergencies, such as hyperkalemia, metabolic acidosis, symptomatic pericardial effusion, or uremic encephalopathy, immediate dialysis is necessary. Care should be taken to initiate dialysis gently to prevent dialysis disequilibrium syndrome, which may manifest as neurologic symptoms due to cerebral edema occurring during or shortly after the procedure.</p>
        <p>Renal transplantation is the most effective renal replacement therapy, offering improved survival and enhanced quality of life compared to dialysis.<xref ref-type="bibr" rid="article-30806.r40">[40]</xref>&#x000a0;While long-term hemodialysis and peritoneal dialysis can serve as temporary measures for patients awaiting transplants or those ineligible for transplantation, early consideration of transplant is crucial. Transplant&#x000a0;should be&#x000a0;considered early (before the need for dialysis) as the waiting list for transplantation is often longer than 2 to 3 years. The Organ Procurement and Transplantation Network (OPTN) suggests referral for a preemptive kidney transplant (before dialysis is needed) when GFR is between 20 and 30, depending on the rate of kidney function decline.</p>
        <p>In addition, preparation for renal replacement therapy, such as hemodialysis or peritoneal dialysis access, should be initiated months before renal replacement is needed to avoid potential complications from emergently starting dialysis.&#x000a0;Most studies show no improvement with initiating dialysis at higher versus lower GFRs, and the decision for dialysis initiation is a clinical decision based on patient signs and symptoms rather than absolute numbers. Uremia is the most common indication for dialysis initiation; therefore, clinicians must be able to recognize the associated characteristics.<xref ref-type="bibr" rid="article-30806.r41">[41]</xref></p>
        <p>Iron replacement should be initiated in patients with anemia of CKD and underlying iron deficiency. This can be administered during dialysis sessions or via oral or intravenous (IV) therapy if dialysis has not yet commenced. Erythropoiesis-stimulating agents, such as erythropoietin or darbepoetin, may also be considered when hemoglobin levels drop below 10 g/dL. See StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/17541">Anemia of Chronic Renal Disease</ext-link>," for more information.<xref ref-type="bibr" rid="article-30806.r42">[42]</xref>&#x000a0;</p>
        <p>Hyperparathyroidism, along with associated or isolated hypocalcemia and hyperphosphatemia, can be managed using several treatment options, including oral calcium carbonate or calcium acetate, oral vitamin D therapy, and oral phosphate binders, such as calcium carbonate, calcium acetate, sevelamer, or lanthanum carbonate. Calcitriol (activated vitamin D) is often necessary for individuals with CKD and ESRD.<xref ref-type="bibr" rid="article-30806.r43">[43]</xref>&#x000a0;See StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/28363">Chronic Kidney Disease-Metabolic Bone Disorder</ext-link>," for more information.<xref ref-type="bibr" rid="article-30806.r44">[44]</xref></p>
        <p>A dietitian should be consulted if dietary alterations are being considered. Patients with CKD should adhere to a diet low in potassium and phosphate, while sodium intake should be restricted to 2 to 3 g. Although&#x000a0;some evidence is conflicting regarding protein intake in kidney failure patients, current recommendations for a low-protein diet before dialysis initiation suggest consuming 0.8 to 1 g of protein per kilogram of body weight daily, with an additional gram of protein for every gram lost in urine for patients with nephrotic syndrome.<xref ref-type="bibr" rid="article-30806.r45">[45]</xref>&#x000a0;</p>
        <p>Significant evidence shows that a low-protein diet helps delay the progression of CKD&#x02014;a strategy widely adopted in certain regions. Although concerns about malnutrition are valid, close nutritional monitoring alongside supplementation as necessary can sufficiently meet all metabolic requirements on a low-protein diet.<xref ref-type="bibr" rid="article-30806.r46">[46]</xref><xref ref-type="bibr" rid="article-30806.r47">[47]</xref>&#x000a0;In addition, significant evidence indicates that adopting a plant-based diet can decelerate the progression of CKD and delay dialysis initiation. Animal protein intake contributes to uremia by elevating nitrogenous waste levels, leading to increased intraglomerular pressure and greater glomerular hyperfiltration.<xref ref-type="bibr" rid="article-30806.r48">[48]</xref><xref ref-type="bibr" rid="article-30806.r49">[49]</xref></p>
        <p>Patients with a creatinine clearance of less than 20 mL/min should exercise caution regarding potassium intake and the use of specific medications, such as potassium-sparing diuretics, ACE inhibitors, angiotensin-receptor blockers, &#x003b2;-blockers, and NSAIDs. In addition, due to the accumulation of uremic toxins and the potential for increased bleeding and hemorrhage risk, prescribing oral anticoagulants or antiplatelet medications to ESRD patients requires careful consideration and monitoring. Nephrotoxic medications such as NSAIDs and aminoglycoside antibiotics should be avoided in all CKD patients. The administration of <italic toggle="yes">N</italic>-acetylcysteine before IV contrast for radiologic imaging may help reduce the risk of nephrotoxicity. However, considering alternative imaging modalities such as MRI is advisable in these patients to prevent the risk of acute kidney injury altogether.<xref ref-type="bibr" rid="article-30806.r50">[50]</xref></p>
      </sec>
      <sec id="article-30806.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Uremia is usually a straightforward diagnosis in the setting of elevated renal function labs. However, similar signs and symptoms can manifest in other conditions as well. For instance, hepatic encephalopathy resulting from hyperammonemia can present with asterixis and changes in mental status. Liver failure may lead to hypoalbuminemia, resembling the presentation of nephrotic syndrome. Congestive heart failure can manifest as pulmonary edema and signs of volume overload. Pericarditis, whether infectious or from other causes, can produce a pericardial rub similar to that seen in uremic pericarditis.</p>
        <p>Furthermore, intoxication from various substances can also induce changes in mental status, and patients with renal failure may experience reduced clearance of certain substances. Electrolyte imbalances, such as hypermagnesemia and hypercalcemia, are additional factors that can lead to alterations in mental status. Differential diagnosis typically relies on basic laboratory studies and a comprehensive assessment of the clinical presentation to distinguish between these various conditions.</p>
      </sec>
      <sec id="article-30806.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for acute kidney injury and kidney failure resulting from reversible causes, such as lupus nephritis, anti-glomerular basement membrane disease, granulomatosis with polyangiitis, thrombotic thrombocytopenic purpura, multiple myeloma, and hemolytic-uremic syndrome, is significantly improved with early diagnosis and prompt initiation of treatment.<xref ref-type="bibr" rid="article-30806.r51">[51]</xref></p>
        <p>Without treatment, the prognosis for uremic patients is poor. However, with dialysis or transplantation, the prognosis significantly improves. Close monitoring is essential as many patients develop complications during treatment. While mortality rates have decreased over the past three decades, individuals with renal failure still face a higher risk of death compared to the general population, especially during the initial months after starting dialysis.&#x000a0;</p>
      </sec>
      <sec id="article-30806.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with uremia can develop various complications, including hyperpigmented skin, severe itching, pericarditis, pericardial effusion, pulmonary edema, valvular calcification, uremic encephalopathy, electrolyte abnormalities, cardiovascular disease, and uremic pancreatitis.</p>
      </sec>
      <sec id="article-30806.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should avoid nephrotoxic medications such as aminoglycoside antibiotics, NSAIDs, and other potential renal toxins. Administering <italic toggle="yes">N</italic>-acetyl-cysteine before and after a radiologic investigation requiring IV contrast can help reduce nephrotoxicity. Providers should also consider alternative radiological investigations, such as ultrasonography or MRI, in such settings to prevent acute kidney injury, especially in patients with diabetes.</p>
        <p>Patients should receive education on adhering to a diet low in sodium, phosphorus, and potassium. Additionally, incorporating prebiotics, synbiotics, probiotics, and laxatives into their diet may help reduce toxin generation.<xref ref-type="bibr" rid="article-30806.r52">[52]</xref>&#x000a0;Evidence supports that a low-protein diet, particularly a plant-based one, can effectively slow the progression of CKD and delay the need for dialysis. Consulting with a dietitian is crucial whenever possible, considering the delicate nutritional status of most CKD patients.</p>
        <p>Patients should receive education about peritoneal dialysis, hemodialysis, and renal transplant options as they approach stage 4 CKD. Early referral to a transplant center can facilitate preemptive renal transplant, leading to better outcomes. Similarly, early referral for establishing dialysis access is linked to improved outcomes in managing kidney disease.</p>
      </sec>
      <sec id="article-30806.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Early recognition of signs and symptoms is crucial, as untreated uremic encephalopathy can advance to coma. Dialysis effectively reverses symptoms but requires close monitoring to prevent dialysis disequilibrium syndrome.&#x000a0;Initial&#x000a0;symptoms of uremic encephalopathy include nausea, anorexia, restlessness, drowsiness, and slowing of concentration and cognitive functions.</p>
        <p>Progression of uremic encephalopathy is marked by increased disorientation, confusion, and potential for bizarre behavior and emotional instability. Without intervention, severe uremic encephalopathy can lead to stupor and coma.&#x000a0;Healthcare providers must maintain vigilance in monitoring for uremic syndromes, particularly due to uremia's impact on the central nervous system.</p>
        <p>The decision to start renal replacement therapy is made clinically and is not solely based on a specific GFR threshold. Patients with uremic encephalopathy typically show clinical improvement after starting dialysis. However, electroencephalographic (EEG) readings may not immediately improve; findings like slowing alpha waves, slow background activity, and intermittent bursts of theta and delta waves may persist. Notably, it may take several months for EEG patterns to improve, and they may not fully return to normal.</p>
        <p>Treating uremic encephalopathy involves addressing many of the same parameters when treating any patient with ESRD, such as correcting associated anemia, regulating calcium or phosphate levels, and monitoring dialysis adequacy. However, globally, only a small percentage of ESRD patients can access renal replacement therapy due to limited healthcare resources. Improving this access in developing nations could significantly extend many lives.</p>
      </sec>
      <sec id="article-30806.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team approach is crucial to mitigate the high morbidity and mortality associated with uremia. This team typically comprises the primary care provider, nephrologist, transplant surgeon, emergency room physician, critical care physician, nurses, technicians, and pharmacists who collaborate to address the significant complications of uremia. Pharmacists ensure patients are not on nephrotoxic medications and receive appropriate treatments such as erythropoiesis-stimulating agents, calcitriol, iron supplements, and phosphate binders as needed. Diabetic nurses educate patients on the importance of blood glucose control, while dietitians inform them about adhering to a low-protein diet and other dietary restrictions. Primary care providers focus on minimizing cardiovascular risk factors through dietary guidance, smoking cessation support, diabetes management, and promoting healthy body weight maintenance.</p>
        <p>Delivering patient-centered care to individuals with uremia demands a coordinated effort among healthcare professionals, including physicians, advanced practice practitioners, nurses, pharmacists, technicians, and other specialists. Fundamental to this approach is the healthcare team's proficiency in clinical skills and expertise necessary for diagnosing, evaluating, and managing this condition effectively. This encompasses the ability to interpret laboratory results accurately, identify potential complications promptly, and recognize the critical nature of addressing uremic symptoms in a timely manner. Collaborating with radiology or general surgery may be necessary for procedures such as dialysis access placement. Using evidence-based guidelines and crafting individualized care plans tailored to each patient's specific needs are essential components of this strategic approach.</p>
        <p>Ethical considerations are paramount in treatment decisions, especially in respecting patient autonomy regarding their healthcare choices. Given the substantial lifestyle changes involved, patients should receive comprehensive education on all renal replacement options. Social workers are critical in coordinating insurance needs and resolving logistical challenges such as transportation for hemodialysis. Clearly defined roles within the interprofessional team ensure each member leverages their expertise for optimal patient care. Effective interprofessional communication fosters a collaborative environment where information is shared, questions are encouraged, and concerns are addressed promptly.</p>
        <p>In addition, healthcare providers should closely monitor patients with altered mental status for possible uremia, allowing for timely initiation of renal replacement therapy and prevention of uremia-related complications. Early recognition is paramount for prompt initiation of renal replacement therapy, which is indicated for symptomatic uremia patients irrespective of their GFR. Proper management strategies, including renal replacement therapy and potential renal transplant referral, improve outcomes, highlighting the importance of preparing patients for these early interventions. Early referral to transplantation centers is associated with enhanced survival and reduced morbidity in uremia patients.</p>
        <p>Finally, care coordination is crucial in ensuring seamless and efficient patient care. Interprofessional healthcare providers, including physicians, advanced practitioners, nurses, and pharmacists, collaborate effectively to streamline a patient's journey&#x000a0;from diagnosis through treatment and follow-up. This coordination helps minimize errors, decrease delays, and improve patient safety, ultimately leading to better outcomes and patient-centered care that prioritizes the well-being and satisfaction of those affected by uremia.</p>
      </sec>
      <sec id="article-30806.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30806&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30806">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/uremia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30806">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30806/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30806">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30806.s16">
        <title>References</title>
        <ref id="article-30806.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lau</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Vaziri</surname>
                <given-names>ND</given-names>
              </name>
            </person-group>
            <article-title>Urea, a true uremic toxin: the empire strikes back.</article-title>
            <source>Clin Sci (Lond)</source>
            <year>2017</year>
            <month>Jan</month>
            <day>01</day>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-12</page-range>
            <pub-id pub-id-type="pmid">27872172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Said</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Uremic neuropathy.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2013</year>
            <volume>115</volume>
            <fpage>607</fpage>
            <page-range>607-12</page-range>
            <pub-id pub-id-type="pmid">23931805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia.</article-title>
            <source>Am J Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>132</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-167</page-range>
            <pub-id pub-id-type="pmid">30145224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fouque</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wee</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kovesdy</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Kopple</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Precision Medicine for Nutritional Management in End-Stage Kidney Disease and Transition to Dialysis.</article-title>
            <source>Semin Nephrol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>383</fpage>
            <page-range>383-396</page-range>
            <pub-id pub-id-type="pmid">30082058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mair</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Sirich</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Uremic Toxin Clearance and Cardiovascular Toxicities.</article-title>
            <source>Toxins (Basel)</source>
            <year>2018</year>
            <month>Jun</month>
            <day>02</day>
            <volume>10</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">29865226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duranton</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Smet</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vanholder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Argiles</surname>
                <given-names>A</given-names>
              </name>
              <collab>European Uremic Toxin Work Group</collab>
            </person-group>
            <article-title>Normal and pathologic concentrations of uremic toxins.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>1258</fpage>
            <page-range>1258-70</page-range>
            <pub-id pub-id-type="pmid">22626821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joshwa</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Fatigue in Patients with Chronic Kidney Disease: Evidence and Measures.</article-title>
            <source>Nephrol Nurs J</source>
            <year>2017</year>
            <season>Jul-Aug</season>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>337</fpage>
            <page-range>337-343</page-range>
            <pub-id pub-id-type="pmid">29160968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mettang</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Uremic Itch Management.</article-title>
            <source>Curr Probl Dermatol</source>
            <year>2016</year>
            <volume>50</volume>
            <fpage>133</fpage>
            <page-range>133-41</page-range>
            <pub-id pub-id-type="pmid">27578082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Specchio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carboni</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chimenti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamburi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nistico'</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations in patients with chronic renal failure on hemodialysis.</article-title>
            <source>Int J Immunopathol Pharmacol</source>
            <year>2014</year>
            <season>Jan-Mar</season>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">24674672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martins</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Magri&#x000e7;o</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Uremic Frost in End-Stage Renal Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Aug</month>
            <day>16</day>
            <volume>379</volume>
            <issue>7</issue>
            <fpage>669</fpage>
            <pub-id pub-id-type="pmid">30110582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puentes</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Dunstan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Escherichia coli Complications in Pediatric Critical Care.</article-title>
            <source>Crit Care Nurs Clin North Am</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>149</fpage>
            <page-range>149-156</page-range>
            <pub-id pub-id-type="pmid">29413210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perna</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Pizza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Nunzio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bellantone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raffaelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cicchella</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Conzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zacchia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trepiccione</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ingrosso</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.</article-title>
            <source>J Ren Nutr</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>453</fpage>
            <page-range>453-457</page-range>
            <pub-id pub-id-type="pmid">29056164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rocco</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Agodoa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Levey</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ornt</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teehan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eknoyan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>546</fpage>
            <page-range>546-55</page-range>
            <pub-id pub-id-type="pmid">16382021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schepers</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Glorieux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cerini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gayrard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Louvet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maugard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Preus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodriguez-Ortiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Argiles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brunet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Massy</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vanholder</surname>
                <given-names>R</given-names>
              </name>
              <collab>European Uremic Toxin Work Group (EUTox)</collab>
            </person-group>
            <article-title>Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation.</article-title>
            <source>Blood Purif</source>
            <year>2010</year>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-87</page-range>
            <pub-id pub-id-type="pmid">21079396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanholder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pletinck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schepers</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Glorieux</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.</article-title>
            <source>Toxins (Basel)</source>
            <year>2018</year>
            <month>Jan</month>
            <day>08</day>
            <volume>10</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29316724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foley</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>The USRDS: what you need to know about what it can and can't tell us about ESRD.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2013</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>845</fpage>
            <page-range>845-51</page-range>
            <pub-id pub-id-type="pmid">23124788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamagata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iseki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nitta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Iino</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Makino</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hishida</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Chronic kidney disease perspectives in Japan and the importance of urinalysis screening.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">18175065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moeller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gioberge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>ESRD patients in 2001: global overview of patients, treatment modalities and development trends.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>2071</fpage>
            <page-range>2071-6</page-range>
            <pub-id pub-id-type="pmid">12454213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gedney</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Dialysis Patient-Centeredness and Precision Medicine: Focus on Incremental Home Hemodialysis and Preserving Residual Kidney Function.</article-title>
            <source>Semin Nephrol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>426</fpage>
            <page-range>426-432</page-range>
            <pub-id pub-id-type="pmid">30082062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bentata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>El Maghraoui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Benabdelhak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haddiya</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Management of hypercalcaemic crisis in adults: Current role of renal replacement therapy.</article-title>
            <source>Am J Emerg Med</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1053</fpage>
            <page-range>1053-1056</page-range>
            <pub-id pub-id-type="pmid">29631925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bentata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hamdi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chemlal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haddiya</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ismaili</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>El Ouafi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Uremic pericarditis in patients with End Stage Renal Disease: Prevalence, symptoms and outcome in 2017.</article-title>
            <source>Am J Emerg Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>464</fpage>
            <page-range>464-466</page-range>
            <pub-id pub-id-type="pmid">29248269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almoznino-Sarafian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shteinshnaider</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tzur</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bar-Chaim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iskhakov</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Efrati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Modai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gorelik</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Anemia in diabetic patients at an internal medicine ward: clinical correlates and prognostic significance.</article-title>
            <source>Eur J Intern Med</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-6</page-range>
            <pub-id pub-id-type="pmid">20206878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pagani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silvestri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Camaschella</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hepcidin and Anemia: A Tight Relationship.</article-title>
            <source>Front Physiol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>1294</fpage>
            <pub-id pub-id-type="pmid">31649559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boccardo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Galbusera</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Platelet dysfunction in renal failure.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>579</fpage>
            <page-range>579-89</page-range>
            <pub-id pub-id-type="pmid">15497100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seliger</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Hyperkalemia in patients with chronic renal failure.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2019</year>
            <month>Dec</month>
            <day>01</day>
            <volume>34</volume>
            <issue>Suppl 3</issue>
            <fpage>iii12</fpage>
            <page-range>iii12-iii18</page-range>
            <pub-id pub-id-type="pmid">31800076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Askar</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Hyperphosphatemia. The hidden killer in chronic kidney disease.</article-title>
            <source>Saudi Med J</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-9</page-range>
            <pub-id pub-id-type="pmid">25629999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raghavan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eknoyan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Uremia: A historical reappraisal of what happened&#x02029;.</article-title>
            <source>Clin Nephrol</source>
            <year>2018</year>
            <month>May</month>
            <volume>89</volume>
            <issue>5</issue>
            <fpage>305</fpage>
            <page-range>305-313</page-range>
            <pub-id pub-id-type="pmid">29451473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kingma</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Simard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Drolet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Simard</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The Physiopathology of Cardiorenal Syndrome: A Review of the Potential Contributions of Inflammation.</article-title>
            <source>J Cardiovasc Dev Dis</source>
            <year>2017</year>
            <month>Nov</month>
            <day>29</day>
            <volume>4</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29367550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dande</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gadbail</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Sarode</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gadbail</surname>
                <given-names>MPM</given-names>
              </name>
              <name>
                <surname>Gondivkar</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gawande</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarode</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sarode</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Oral Manifestations in Diabetic and Nondiabetic Chronic Renal Failure Patients receiving Hemodialysis.</article-title>
            <source>J Contemp Dent Pract</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>398</fpage>
            <page-range>398-403</page-range>
            <pub-id pub-id-type="pmid">29728543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Husain-Syed</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vanholder</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Uremic encephalopathy.</article-title>
            <source>Kidney Int</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>101</volume>
            <issue>2</issue>
            <fpage>227</fpage>
            <page-range>227-241</page-range>
            <pub-id pub-id-type="pmid">34736971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galeano-Piedrahita</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chiquito-Garc&#x000ed;a</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mej&#x000ed;a-Giraldo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Ruiz</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Uremic Frost: Dialytic Emergency.</article-title>
            <source>Skinmed</source>
            <year>2020</year>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>244</fpage>
            <page-range>244-245</page-range>
            <pub-id pub-id-type="pmid">33032691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dioguardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caloro</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Troiano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giannatempo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Laino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Petruzzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lo Muzio</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Oral manifestations in chronic uremia patients.</article-title>
            <source>Ren Fail</source>
            <year>2016</year>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">26513593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massy</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Liabeuf</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Middle-Molecule Uremic Toxins and Outcomes in Chronic Kidney Disease.</article-title>
            <source>Contrib Nephrol</source>
            <year>2017</year>
            <volume>191</volume>
            <fpage>8</fpage>
            <page-range>8-17</page-range>
            <pub-id pub-id-type="pmid">28910787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klotman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>HIV and the Kidney: From HIV-Associated Nephropathy to Reservoir.</article-title>
            <source>Am J Med Sci</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>358</volume>
            <issue>6</issue>
            <fpage>381</fpage>
            <page-range>381-383</page-range>
            <pub-id pub-id-type="pmid">31813464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Usui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Iseki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iseki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kashihara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nangaku</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Observation period for changes in proteinuria and risk prediction of end-stage renal disease in general population.</article-title>
            <source>Nephrology (Carlton)</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>821</fpage>
            <page-range>821-829</page-range>
            <pub-id pub-id-type="pmid">28635004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuiano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Comi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Caglioti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Nicola</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Iodice</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andreucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Andreucci</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>Current indications for renal biopsy: a questionnaire-based survey.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>448</fpage>
            <page-range>448-57</page-range>
            <pub-id pub-id-type="pmid">10692270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leong</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sao</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Taussig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Plummer</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Sirich</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Residual Function Effectively Controls Plasma Concentrations of Secreted Solutes in Patients on Twice Weekly Hemodialysis.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>7</issue>
            <fpage>1992</fpage>
            <page-range>1992-1999</page-range>
            <pub-id pub-id-type="pmid">29728422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rehman</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Betancor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rivas</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Asher</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Uremic pericarditis, pericardial effusion, and constrictive pericarditis in end-stage renal disease: Insights and pathophysiology.</article-title>
            <source>Clin Cardiol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>10</issue>
            <fpage>839</fpage>
            <page-range>839-846</page-range>
            <pub-id pub-id-type="pmid">28873222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ghio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lepore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Massella</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Molino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peruzzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Emma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fede</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trivelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maringhini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Materassi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Murer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pecoraro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pennesi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse.</article-title>
            <source>Ital J Pediatr</source>
            <year>2017</year>
            <month>Apr</month>
            <day>21</day>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <pub-id pub-id-type="pmid">28427453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kostro</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Hellmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kobiela</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sk&#x000f3;ra</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lichodziejewska-Niemierko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D&#x00119;bska-&#x0015a;lizie&#x00144;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x0015a;ledzi&#x00144;ski</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Quality of Life After Kidney Transplantation: A Prospective Study.</article-title>
            <source>Transplant Proc</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-4</page-range>
            <pub-id pub-id-type="pmid">26915842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivara</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Mehrotra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Timing of Dialysis Initiation: What Has Changed Since IDEAL?</article-title>
            <source>Semin Nephrol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-193</page-range>
            <pub-id pub-id-type="pmid">28410652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r42">
          <label>42</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Anemia of Chronic Kidney Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>7</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">30969693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perry</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Plosker</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.</article-title>
            <source>Drugs</source>
            <year>2014</year>
            <month>May</month>
            <volume>74</volume>
            <issue>7</issue>
            <fpage>771</fpage>
            <page-range>771-92</page-range>
            <pub-id pub-id-type="pmid">24811546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r44">
          <label>44</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <chapter-title>Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">32809577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Byham-Gray</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Scott Parrott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rigassio-Radler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mandayam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Mitch</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Osama Gaber</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The mean dietary protein intake at different stages of chronic kidney disease is higher than current guidelines.</article-title>
            <source>Kidney Int</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>724</fpage>
            <page-range>724-32</page-range>
            <pub-id pub-id-type="pmid">23302719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garneata</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stancu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dragomir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stefan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mircescu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>2164</fpage>
            <page-range>2164-76</page-range>
            <pub-id pub-id-type="pmid">26823552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Tortorici</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>St-Jules</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Aoun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rojas-Bautista</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tschida</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vassalotti</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kovesdy</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>North American experience with Low protein diet for Non-dialysis-dependent chronic kidney disease.</article-title>
            <source>BMC Nephrol</source>
            <year>2016</year>
            <month>Jul</month>
            <day>19</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <pub-id pub-id-type="pmid">27435088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schlueter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown-Tortorici</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Streja</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tantisattamo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferrey</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JLT</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Kovesdy</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease.</article-title>
            <source>Nutrients</source>
            <year>2020</year>
            <month>Jun</month>
            <day>29</day>
            <volume>12</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">32610641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The role of low protein diet in ameliorating proteinuria and deferring dialysis initiation: what is old and what is new.</article-title>
            <source>Panminerva Med</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-165</page-range>
            <pub-id pub-id-type="pmid">27759735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leurs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Machowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lindholm</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Timing of dialysis initiation: when to start? Which treatment?</article-title>
            <source>J Ren Nutr</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>238</fpage>
            <page-range>238-41</page-range>
            <pub-id pub-id-type="pmid">25556306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zendejas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Faldu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Andreoni</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Outcome of kidney transplants for adults with hemolytic uremic syndrome in the U.S.: a ten-year database analysis.</article-title>
            <source>Ann Transplant</source>
            <year>2014</year>
            <month>Jul</month>
            <day>21</day>
            <volume>19</volume>
            <fpage>353</fpage>
            <page-range>353-61</page-range>
            <pub-id pub-id-type="pmid">25042028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30806.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sumida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Kovesdy</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Microbiome modulation as a novel therapeutic approach in chronic kidney disease.</article-title>
            <source>Curr Opin Nephrol Hypertens</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-84</page-range>
            <pub-id pub-id-type="pmid">33148949</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
